Impact of SGLT-2 Inhibition on Cardiometabolic Abnormalities in a Rat Model of Polycystic Ovary Syndrome

Impact of SGLT-2 Inhibition on Cardiometabolic Abnormalities in a Rat Model of Polycystic Ovary Syndrome

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in reproductive-age women. PCOS is characterized by hyperandrogenism and ovulatory dysfunction. Women with PCOS have a high prevalence of obesity, insulin resistance (IR), increased blood pressure (BP), and activation of the reni...

Full description

Bibliographic Details
Main Authors:	Jacob E. Pruett, Edgar D. Torres Fernandez, Steven J. Everman, Ruth M. Vinson, Kacey Davenport, Madelyn K. Logan, Stephanie A. Ye, Damian G. Romero, Licy L. Yanes Cardozo
Format:	Article
Language:	English
Published:	MDPI AG 2021-03-01
Series:	International Journal of Molecular Sciences
Subjects:	polycystic ovary syndrome androgens obesity renin-angiotensin system blood pressure sodium glucose cotransporter-2
Online Access:	https://www.mdpi.com/1422-0067/22/5/2576

Similar Items

Mitochondrial function and oxidative stress in white adipose tissue in a rat model of PCOS: effect of SGLT2 inhibition
by: Jacob E. Pruett, et al.
Published: (2022-08-01)

Obesity-associated cardiometabolic complications in polycystic ovary syndrome: The potential role of sodium-glucose cotransporter-2 inhibitors
by: Jacob E. Pruett, et al.
Published: (2023-02-01)

Association of insertion/deletion polymorphism of angiotensin converting enzyme gene with metabolic components of polycystic ovary syndrome
by: Susmita Banerjee, et al.
Published: (2022-08-01)

Cardiac and Renal SARS-CoV-2 Viral Entry Protein Regulation by Androgens and Diet: Implications for Polycystic Ovary Syndrome and COVID-19
by: Samar Rezq, et al.
Published: (2021-09-01)

Trehalosemodulates OVRAS to improve oxidative stress and apoptosis in KGN cells and ovaries of PCOS mice
by: Shasha Gao, et al.
Published: (2024-01-01)

SARS-CoV-2 Viral Entry Proteins in Hyperandrogenemic Female Mice: Implications for Women with PCOS and COVID-19
by: Alexandra M. Huffman, et al.
Published: (2021-04-01)

Relationship between IL-17 and ambulatory blood pressure inpolycystic ovary syndrome
by: Fatemeh Foroozanfard, et al.
Published: (2017-01-01)

The role of B cells in immune cell activation in polycystic ovary syndrome
by: Angelo Ascani, et al.
Published: (2023-07-01)

Relationship between levels of androgen hormones, hirsutism and acne with depression and anxiety in women with polycystic ovary syndrome
by: Saeideh Mehrabadi, et al.
Published: (2019-07-01)

Phenotypes of polycystic ovary syndrome and accompanying hormonal disturbances
by: Karatas Savas, et al.
Published: (2022-12-01)

Shapes of the uterine cavity are different in women with polycystic ovary syndrome
by: Shunsaku Fujii, et al.
Published: (2023-01-01)

The interplay between androgens and the immune response in polycystic ovary syndrome
by: Sania Shabbir, et al.
Published: (2023-04-01)

Renin-Angiotensin System overactivation in polycystic ovary syndrome, a risk for SARS-CoV-2 infection?
by: Abu Saleh Md Moin, et al.
Published: (2020-09-01)

Comparison of the metabolic parameters and androgen level of umbilical cord blood in newborns of mothers with polycystic ovary syndrome and controls
by: Ferdous Mehrabian, et al.
Published: (2012-01-01)

Polycystic ovary syndrome resembling histopathological alterations in ovaries from prenatal androgenized female rats
by: Wang Fang, et al.
Published: (2012-05-01)

Prenatal kisspeptin antagonist exposure prevents polycystic ovary syndrome development in prenatally-androgenized rats in adulthood: An experimental study
by: Elahe Sadeghian Bakhi, et al.
Published: (2023-02-01)

Foetal Sonographic Anogenital Distance Is Longer in Polycystic Ovary Syndrome Mothers
by: Sharon Perlman, et al.
Published: (2020-09-01)

Current Advances in Cellular Approaches for Pathophysiology and Treatment of Polycystic Ovary Syndrome
by: Yi-Ru Tsai, et al.
Published: (2023-08-01)

Relationship between Androgen and Glucose Metabolism in Patients with Polycystic Ovary Syndrome
by: WENG Ruiwen, LIU Yi, ZHANG Wei, LIU Hengwei
Published: (2022-11-01)

Role of Anti-Müllerian Hormone in the Pathogenesis of Polycystic Ovary Syndrome
by: Didier Dewailly, et al.
Published: (2020-09-01)

Ovarian volume, not follicle count, is independently associated with androgens in patients with polycystic ovary syndrome
by: Asieh Mansour, et al.
Published: (2022-12-01)

Impaired Prolactin-Lowering Effects of Metformin in Women with Polycystic Ovary Syndrome
by: Robert Krysiak, et al.
Published: (2023-08-01)

High androgen concentrations in follicular fluid of polycystic ovary syndrome women
by: Alice Bongrani, et al.
Published: (2022-06-01)

The effects of exercise on cardiometabolic outcomes in women with polycystic ovary syndrome not taking the oral contraceptive pill: protocol for a systematic review and meta-analysis
by: Amie Woodward, et al.
Published: (2019-05-01)

Polycystic Ovary Syndrome in Adolescence
by: Rebecca Deans
Published: (2019-10-01)

Evaluation of CAG repeat length in the androgen receptor gene and polycystic ovary syndrome risk in Iranian women: A case-control study
by: Hamideh Arasteh, et al.
Published: (2022-03-01)

Correlation Analysis between Different Free Testosterone Index Levels and Clinical Characteristics of Patients with Polycystic Ovary Syndrome
by: FENG Xiaoling, YIN Wenqing, WANG Ying, HOU Lihui
Published: (2023-08-01)

Impact of Short-Term Isoflavone Intervention in Polycystic Ovary Syndrome (PCOS) Patients on Microbiota Composition and Metagenomics
by: Christoph Haudum, et al.
Published: (2020-06-01)

Androgen Excess Induced Mitochondrial Abnormality in Ovarian Granulosa Cells in a Rat Model of Polycystic Ovary Syndrome
by: Linyi Song, et al.
Published: (2022-03-01)

Serum metabolomics profiling by proton nuclear magnetic resonance spectroscopy reveals sexual dimorphism and masculinization of intermediate metabolism in women with polycystic ovary syndrome (PCOS)
by: Héctor F. Escobar-Morreale, et al.
Published: (2023-04-01)

A Systematic Review of Anogenital Distance and Gynecological Disorders: Endometriosis and Polycystic Ovary Syndrome
by: Zhenyan Pan, et al.
Published: (2021-07-01)

Berberine in the treatment of polycystic ovary syndrome
by: Łukasz Ochyra, et al.
Published: (2022-04-01)

Age related endocrine patterns observed in polycystic ovary syndrome patients vs. ovulatory controls: descriptive data from a university based infertility center
by: Batool Hossein Rashidi, et al.
Published: (2016-10-01)

Metabolic and endocrine connections of 17-hydroxypregnenolone in polycystic ovary syndrome women
by: Sebastião Freitas de Medeiros, et al.
Published: (2017-09-01)

Investigation of androgen receptor CAG repeats length in polycystic ovary syndrome diagnosed using the new international evidence-based guideline
by: Xueqi Yan, et al.
Published: (2023-11-01)

Estrogen Receptors in Polycystic Ovary Syndrome
by: Xue-Ling Xu, et al.
Published: (2021-02-01)

Unravelling Polycystic Ovary Syndrome and Its Comorbidities
by: Kyung-Wook Kim
Published: (2021-09-01)

The Relationship between Vitamin D Metabolites and Androgens in Women with Polycystic Ovary Syndrome
by: Jakub Mesinovic, et al.
Published: (2020-04-01)

Relation Between Non-Alcoholic Fatty Pancreas and Clinical and Biochemical Parameters in Women with Polycystic Ovary Syndrome: A Multi-Centric Study
by: Osman MAA, et al.
Published: (2022-11-01)

Impact of vitamin D supplementation on cardio-metabolic status and androgen profile in women with polycystic ovary syndrome: placebo-controlled clinical trial
by: Nearmeen M. Rashad, et al.
Published: (2019-11-01)